NZ601729A - Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant - Google Patents
Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvantInfo
- Publication number
- NZ601729A NZ601729A NZ601729A NZ60172911A NZ601729A NZ 601729 A NZ601729 A NZ 601729A NZ 601729 A NZ601729 A NZ 601729A NZ 60172911 A NZ60172911 A NZ 60172911A NZ 601729 A NZ601729 A NZ 601729A
- Authority
- NZ
- New Zealand
- Prior art keywords
- virus
- particle
- adjuvant
- composition
- amyloid beta
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000002671 adjuvant Substances 0.000 title abstract 2
- 239000002245 particle Substances 0.000 title abstract 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 abstract 1
- 239000004147 Sorbitan trioleate Substances 0.000 abstract 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 abstract 1
- 159000000013 aluminium salts Chemical class 0.000 abstract 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 abstract 1
- 108010088515 amyloid beta-protein (1-6) Proteins 0.000 abstract 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000007764 o/w emulsion Substances 0.000 abstract 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 1
- 229920000053 polysorbate 80 Polymers 0.000 abstract 1
- 235000019337 sorbitan trioleate Nutrition 0.000 abstract 1
- 229960000391 sorbitan trioleate Drugs 0.000 abstract 1
- 229940031439 squalene Drugs 0.000 abstract 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10158273 | 2010-03-29 | ||
| US36169710P | 2010-07-06 | 2010-07-06 | |
| PCT/EP2011/054735 WO2011120924A1 (en) | 2010-03-29 | 2011-03-28 | Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ601729A true NZ601729A (en) | 2013-10-25 |
Family
ID=42285305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ601729A NZ601729A (en) | 2010-03-29 | 2011-03-28 | Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US20130011431A1 (enExample) |
| EP (1) | EP2552489A1 (enExample) |
| JP (2) | JP6088422B2 (enExample) |
| KR (1) | KR20130018407A (enExample) |
| CN (2) | CN104436212A (enExample) |
| AR (1) | AR080810A1 (enExample) |
| AU (1) | AU2011234656B2 (enExample) |
| BR (1) | BR112012024708A2 (enExample) |
| CA (1) | CA2793580A1 (enExample) |
| CL (1) | CL2012002685A1 (enExample) |
| CO (1) | CO6630127A2 (enExample) |
| EC (1) | ECSP12012180A (enExample) |
| GT (1) | GT201200265A (enExample) |
| IL (1) | IL221540B (enExample) |
| MA (1) | MA34084B1 (enExample) |
| MX (1) | MX2012011340A (enExample) |
| NZ (1) | NZ601729A (enExample) |
| PE (1) | PE20130642A1 (enExample) |
| PH (1) | PH12012501683A1 (enExample) |
| RU (1) | RU2603486C2 (enExample) |
| SG (2) | SG10201505374TA (enExample) |
| TN (1) | TN2012000431A1 (enExample) |
| TW (2) | TW201618806A (enExample) |
| WO (1) | WO2011120924A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015017280A1 (en) | 2013-07-28 | 2015-02-05 | Qantu Therapeutics, Inc. | Vaccine formulations that induce a th2 immune response |
| WO2015165964A1 (en) * | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| WO2015165961A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| WO2015165971A1 (en) * | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| ES2824763T3 (es) * | 2014-04-29 | 2021-05-13 | Frank Mattner | Tratamiento y a la prevención de la enfermedad de Alzheimer (AD) |
| EP3137094B1 (en) | 2014-04-29 | 2022-12-07 | ADvantage Therapeutics, Inc. | Treatment and prevention of alzheimer's disease (ad) |
| ES2571055B1 (es) * | 2016-02-15 | 2016-12-28 | Araclon Biotech, S.L. | Conjugado amiloide y usos y procedimientos del mismo |
| AU2020348947B2 (en) | 2019-09-16 | 2025-11-27 | Amgen Inc. | Method for external sterilization of drug delivery device |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU201906B (en) | 1987-03-04 | 1991-01-28 | Sandoz Ag | Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them |
| US6153201A (en) * | 1993-03-09 | 2000-11-28 | University Of Rochester | Oral immunization with papillomavirus virus-like particles |
| FR2734484B1 (fr) * | 1995-05-24 | 1997-06-27 | Pasteur Merieux Serums Vacc | Composition vaccinale liquide et procede de fabrication |
| CA2295740A1 (en) * | 1997-07-08 | 1999-01-21 | Chiron Corporation | Use of submicron oil-in-water emulsions with dna vaccines |
| EP1409013B1 (en) * | 2001-07-26 | 2009-11-18 | Novartis Vaccines and Diagnostics S.r.l. | Vaccines comprising aluminium adjuvants and histidine |
| MXPA05000819A (es) * | 2002-07-19 | 2005-08-29 | Cytos Biotechnology Ag | Composiciones de vacunas que contienen arreglos de antigeno amiloide beta 1-6. |
| CN100409896C (zh) * | 2003-03-31 | 2008-08-13 | 姚志彬 | 一种老年性痴呆疫苗及其制备方法 |
| WO2006032674A1 (en) * | 2004-09-21 | 2006-03-30 | Cytos Biotechnology Ag | Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide |
| GB0424563D0 (en) * | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| CN101318015A (zh) * | 2008-06-25 | 2008-12-10 | 中山大学 | 老年性痴呆重组蛋白疫苗及其制备方法 |
-
2011
- 2011-03-28 TW TW104125184A patent/TW201618806A/zh unknown
- 2011-03-28 AU AU2011234656A patent/AU2011234656B2/en not_active Ceased
- 2011-03-28 BR BR112012024708A patent/BR112012024708A2/pt not_active Application Discontinuation
- 2011-03-28 CN CN201410789825.6A patent/CN104436212A/zh active Pending
- 2011-03-28 MX MX2012011340A patent/MX2012011340A/es active IP Right Grant
- 2011-03-28 CA CA2793580A patent/CA2793580A1/en not_active Abandoned
- 2011-03-28 JP JP2013501791A patent/JP6088422B2/ja not_active Expired - Fee Related
- 2011-03-28 AR ARP110101001A patent/AR080810A1/es not_active Application Discontinuation
- 2011-03-28 MA MA35241A patent/MA34084B1/fr unknown
- 2011-03-28 TW TW100110650A patent/TW201138805A/zh unknown
- 2011-03-28 US US13/578,017 patent/US20130011431A1/en not_active Abandoned
- 2011-03-28 EP EP11711322A patent/EP2552489A1/en not_active Withdrawn
- 2011-03-28 SG SG10201505374TA patent/SG10201505374TA/en unknown
- 2011-03-28 SG SG2012060554A patent/SG183806A1/en unknown
- 2011-03-28 WO PCT/EP2011/054735 patent/WO2011120924A1/en not_active Ceased
- 2011-03-28 PE PE2012001825A patent/PE20130642A1/es not_active Application Discontinuation
- 2011-03-28 CN CN2011800162176A patent/CN102834118A/zh active Pending
- 2011-03-28 NZ NZ601729A patent/NZ601729A/xx not_active IP Right Cessation
- 2011-03-28 KR KR1020127025613A patent/KR20130018407A/ko not_active Ceased
- 2011-03-28 PH PH1/2012/501683A patent/PH12012501683A1/en unknown
- 2011-03-28 RU RU2012145734/15A patent/RU2603486C2/ru not_active IP Right Cessation
-
2012
- 2012-08-20 IL IL221540A patent/IL221540B/en not_active IP Right Cessation
- 2012-08-30 TN TNP2012000431A patent/TN2012000431A1/en unknown
- 2012-09-25 EC ECSP12012180 patent/ECSP12012180A/es unknown
- 2012-09-26 GT GT201200265A patent/GT201200265A/es unknown
- 2012-09-27 CL CL2012002685A patent/CL2012002685A1/es unknown
- 2012-10-01 CO CO12171902A patent/CO6630127A2/es unknown
-
2014
- 2014-08-11 US US14/456,562 patent/US20140348871A1/en not_active Abandoned
-
2015
- 2015-06-26 US US14/751,492 patent/US20150297692A1/en not_active Abandoned
- 2015-12-17 US US14/972,187 patent/US20160101167A1/en not_active Abandoned
-
2016
- 2016-06-09 JP JP2016115660A patent/JP2017008035A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ601729A (en) | Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant | |
| CA2883751C (en) | Methods of treating alzheimer's disease and pharmaceutical compositions thereof | |
| EP4241785A3 (en) | Influenza virus vaccines and uses thereof | |
| EA201270657A1 (ru) | Поливинилпирролидон для стабилизации твердой дисперсии некристаллической формы ротиготина | |
| EP2813220A3 (en) | Method for formulating large diameter synthetic membrane vesicles | |
| MX343048B (es) | Oligodesoxinucleotidos inmunoestimulantes. | |
| MX2010008468A (es) | Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante. | |
| PH12013502442A1 (en) | Inactivated dengue virus vaccine | |
| MX2013013801A (es) | Oligodesoxinucleotidos inmunoestimuladores. | |
| EP2105129A3 (en) | Encapsulated Vaccines for the Oral Vaccination and Boostering of Fish and Other Animals | |
| NZ598654A (en) | Immunogenic compositions including tlr activity modulators | |
| PH12015501637A1 (en) | Inactivated dengue virus vaccine with aluminium-free adjuvant | |
| CA2763359C (en) | New human rotavirus strains and vaccines | |
| MX346596B (es) | Oligodesoxinucleotidos inmunoestimuladores. | |
| WO2010082220A3 (en) | Sustained release pharmaceutical composition of quetiapine and process for preparation thereof | |
| MX2012008413A (es) | Composicion novedosa de retigabina. | |
| MX2015001917A (es) | Composiciones farmaceuticas de memantina. | |
| MX341918B (es) | Formulación de liposomas adecuada para tratar o prevenir la tuberculosis. | |
| FI20115374A0 (fi) | Uudet hypoallergeenit | |
| MX376783B (es) | Liposomas que encapsulan un autoantígeno y su uso en la prevención y/o el tratamiento de enfermedades autoinmunes. | |
| UA105285C2 (uk) | Тверда фармацевтична композиція раміприлу і безилату амлодипіну і її отримання | |
| EA201170569A1 (ru) | Лекарственное средство для повышения дозы противоаллергической вакцины | |
| EP3599247A3 (en) | Recombinant hemagglutinin protein of influenza virus and vaccine containing the same | |
| EP4351638A4 (en) | VACCINE WITH VIRUS-LIKE PARTICLES FOR CORONAVIRUS | |
| WO2011074006A3 (en) | Vaccine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| ERR | Error or correction |
Free format text: THE OWNER HAS BEEN CORRECTED TO 890887, NOVARTIS AG, LICHTSTRASSE 35, CH-4056 BASEL, CH Effective date: 20140409 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAR 2016 BY CPA GLOBAL Effective date: 20150213 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAR 2017 BY CPA GLOBAL Effective date: 20160212 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAR 2018 BY CPA GLOBAL Effective date: 20170217 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAR 2019 BY CPA GLOBAL Effective date: 20180222 |
|
| LAPS | Patent lapsed |